-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Hengrui Pharmaceutical, the "first brother of medicine", announced that Zou Jianjun, the company's deputy general manager, applied for his resignation as the company's deputy general manager due to personal reasons
.
According to the data, Zou Jianjun has been deeply involved in oncology and served as the head of related businesses of Bayer China, Celgene, and Hengrui Medicine.
He joined Hengrui Medicine in September 2015 and has worked in Hengrui Medicine for more than six years
.
Zou Jianjun is not the first executive from Hengrui to leave in recent years
.
The announcement shows that in the past year, Hengrui Medicine has had 4 core executives resign, including 2 deputy general managers, 1 chairman, and 1 chief financial officer
.
Specifically, on February 25, 2022, Zhang Yuehong applied for his resignation as deputy general manager for personal reasons and no longer held any positions in the company
.
According to the data, Zhang Yuehong’s work is mainly related to human resources.
From 2015 to 2018, he worked at Novartis’ Swiss headquarters as the human resources director.
Later, he joined Hengrui Medicine as the chief human resources officer in 2018, and he became the vice president in 2020.
Manager job
.
In November 2021, Zhou Song resigned from the position of Chief Financial Officer of Hengrui Medicine due to personal reasons
.
After resigning from the above positions, Zhou Song is still working in the company
.
The company's annual report disclosed in 2020 shows that Zhou Song received a total of 741,100 yuan in pre-tax remuneration from the company
.
In July 2021, Zhou Yunshu, the former chairman and general manager, resigned from the chairman and other positions due to physical reasons, which aroused great attention and heated discussions in the industry
.
According to the data, after graduating from China Pharmaceutical University, he joined Hengrui Medicine and served as the deputy director of the development department, deputy general manager, general manager, and director.
He has successively been in charge of research and development, human resources, corporate operations, sales and other work
.
In January 2020, Hengrui Medicine announced that Zhou Yunshu would be the chairman of the board, and Sun Piaoyang had resigned as the chairman, and instead served as a director of the company and chairman of the strategy committee
.
After this news was released, Zhou Yunshu was also regarded as Sun Piaoyang's successor, but it took only a year and a half for him to take office as chairman and to leave
.
And Sun Piaoyang, who had already been disarmed and returned to the field, had to return to the front of the stage to act as the acting chairman
.
The changes of many core management personnel in the first year of medicine have attracted the attention of the market
.
According to public information, after the announcement of Zou Jianjun's resignation, Hengrui Medicine quickly appointed two new R&D executives, namely Zhang Xiaojing, deputy general manager and chief medical executive (tumor), and Wang Quanren, deputy general manager
.
Hengrui hopes that their promotion will help the company to further strengthen its internal R&D and innovation capabilities, and accelerate the pace of company innovation
.
In recent years, with the advancement of the new medical reform policy, the transformation and upgrading of the pharmaceutical industry has accelerated, and Hengrui is also accelerating innovation and transformation, including through continuous increase in R&D investment, active cooperation and introduction and other measures to accelerate progress on the road of innovative drug transformation
.
In recent years, Hengrui Medicine's R&D investment has maintained a rapid growth of about 30%, and the proportion of R&D investment in sales revenue has remained around 20%
.
However, the transformation of pharmaceutical innovation is not easy, and the transformation pains of enterprises are beginning to appear
.
Hengrui Medicine once stated that due to the severe homogenization competition in the domestic innovative biopharmaceutical industry and the rapid rise in costs of R&D, manpower, and production, biopharmaceutical innovation is facing severe challenges
.
The industry believes that with the vigorous development of the domestic innovative drug market, talents have become one of the important gaps for various pharmaceutical companies
.
In order to accelerate forward, pharmaceutical companies need to think about how to retain talents while investing heavily in hiring talents
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to the data, Zou Jianjun has been deeply involved in oncology and served as the head of related businesses of Bayer China, Celgene, and Hengrui Medicine.
He joined Hengrui Medicine in September 2015 and has worked in Hengrui Medicine for more than six years
.
Zou Jianjun is not the first executive from Hengrui to leave in recent years
.
The announcement shows that in the past year, Hengrui Medicine has had 4 core executives resign, including 2 deputy general managers, 1 chairman, and 1 chief financial officer
.
Specifically, on February 25, 2022, Zhang Yuehong applied for his resignation as deputy general manager for personal reasons and no longer held any positions in the company
.
According to the data, Zhang Yuehong’s work is mainly related to human resources.
From 2015 to 2018, he worked at Novartis’ Swiss headquarters as the human resources director.
Later, he joined Hengrui Medicine as the chief human resources officer in 2018, and he became the vice president in 2020.
Manager job
.
In November 2021, Zhou Song resigned from the position of Chief Financial Officer of Hengrui Medicine due to personal reasons
.
After resigning from the above positions, Zhou Song is still working in the company
.
The company's annual report disclosed in 2020 shows that Zhou Song received a total of 741,100 yuan in pre-tax remuneration from the company
.
In July 2021, Zhou Yunshu, the former chairman and general manager, resigned from the chairman and other positions due to physical reasons, which aroused great attention and heated discussions in the industry
.
According to the data, after graduating from China Pharmaceutical University, he joined Hengrui Medicine and served as the deputy director of the development department, deputy general manager, general manager, and director.
He has successively been in charge of research and development, human resources, corporate operations, sales and other work
.
In January 2020, Hengrui Medicine announced that Zhou Yunshu would be the chairman of the board, and Sun Piaoyang had resigned as the chairman, and instead served as a director of the company and chairman of the strategy committee
.
After this news was released, Zhou Yunshu was also regarded as Sun Piaoyang's successor, but it took only a year and a half for him to take office as chairman and to leave
.
And Sun Piaoyang, who had already been disarmed and returned to the field, had to return to the front of the stage to act as the acting chairman
.
The changes of many core management personnel in the first year of medicine have attracted the attention of the market
.
According to public information, after the announcement of Zou Jianjun's resignation, Hengrui Medicine quickly appointed two new R&D executives, namely Zhang Xiaojing, deputy general manager and chief medical executive (tumor), and Wang Quanren, deputy general manager
.
Hengrui hopes that their promotion will help the company to further strengthen its internal R&D and innovation capabilities, and accelerate the pace of company innovation
.
In recent years, with the advancement of the new medical reform policy, the transformation and upgrading of the pharmaceutical industry has accelerated, and Hengrui is also accelerating innovation and transformation, including through continuous increase in R&D investment, active cooperation and introduction and other measures to accelerate progress on the road of innovative drug transformation
.
In recent years, Hengrui Medicine's R&D investment has maintained a rapid growth of about 30%, and the proportion of R&D investment in sales revenue has remained around 20%
.
However, the transformation of pharmaceutical innovation is not easy, and the transformation pains of enterprises are beginning to appear
.
Hengrui Medicine once stated that due to the severe homogenization competition in the domestic innovative biopharmaceutical industry and the rapid rise in costs of R&D, manpower, and production, biopharmaceutical innovation is facing severe challenges
.
The industry believes that with the vigorous development of the domestic innovative drug market, talents have become one of the important gaps for various pharmaceutical companies
.
In order to accelerate forward, pharmaceutical companies need to think about how to retain talents while investing heavily in hiring talents
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
